Please use this identifier to cite or link to this item:
|Title: ||Evidence of involvement of the human Par-4 (PAWR) gene in major depressive disorder.|
|Authors: ||Liou YJ|
|Issue Date: ||2018-10-12T07:23:07Z
|Publisher: ||World J Biol Psychiatry.|
|Abstract: ||Abstract: QBJECTIVES: The aim of the study was to examine the associations between genetic variations in the human PAWR gene and major depressive disorder (MDD) as well as the response to antidepressant treatment.
METHODS:Six-hundred and two patients with MDD and 543 controls were included in the study; among the MDD patients, 268 were followed-up for a further 8 weeks in order to assess their response to treatment with selective serotonin reuptake inhibitors (SSRIs). Six polymorphisms (rs17005769, rs4842318, rs7305141, rs2307223, rs8176874 and rs2307220) of the PAWR gene were investigated with regard to their association with MDD and antidepressant treatment efficacy.
RESULTS:One polymorphism, rs8176874, was in genotypic (uncorrected P=0.005) and allelic (uncorrected P=0.0015) association with MDD. Several haplotypes spanning rs7305141-rs2307223-rs8176874 were also significantly associated with MDD after correction for multiple testing (corrected P<0.05). However, neither single-marker nor haplotype-based analyses suggested an association between the studied markers and SSRI treatment response.
CONCLUSIONS:Genetic variations in the PAWR gene are related to susceptibility to MDD but not to SSRI treatment response.
|Relation: ||12(4) pp.288-295|
|Appears in Collections:||[生命科學暨生物科技學系] 期刊論文|
Files in This Item:
All items in NTOUR are protected by copyright, with all rights reserved.